Hormonal Response / Post Bariatric Hypoglycemia / Sleeve gastrectomy with duodenojejunal bypass · Interventional Study

Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity: A Prospective Single-Center Non-Inferiority Randomized Clinical Trial

ClinicalTrials.gov · August 5, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a prospective, single-center, non-inferiority randomized controlled trial comparing hormonal responses (GLP-1, GIP, glucagon, insulin) between laparoscopic sleeve gastrectomy with duodenojejunal bypass and Roux-en-Y gastric bypass in patients with super morbid obesity. The trial is currently recruiting and has not yet reported any results.

What was studied

Interventional, Randomized, Parallel, Open label, Treatment purpose. Bariatric Surgery, Hormonal Response, Post Bariatric Hypoglycemia; age from 18 Years; to 60 Years. Intervention: Sleeve gastrectomy with duodenojejunal bypass. Compared with: Roux-en-Y gastric bypass — Active Comparator. n = 32. 1 site: Thailand.

Key findings

Safety

Secondary outcomes, safety endpoints, and incidence of post-bariatric hypoglycemia outcomes not yet available.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registered but actively recruiting trial with no results posted; hormonal and safety outcomes remain unmeasured and unreported.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Hormonal response (assessed at Post-operative 6-24 months)

DesignInterventional, Randomized, Parallel, Open label, Treatment purpose

PopulationBariatric Surgery, Hormonal Response, Post Bariatric Hypoglycemia; age from 18 Years; to 60 Years

Sample size32

InterventionSleeve gastrectomy with duodenojejunal bypass

ComparatorRoux-en-Y gastric bypass — Active Comparator

Setting1 site: Thailand

Reported figures

Quoted from the source exactly as published.

Planned sample size32

Primary outcome measureHormonal response (GLP-1, GIP, glucagon, insulin), post-operative 6–24 months

Study typeInterventional, non-inferiority design

Caveats

No results are reported in this registry record; study is actively recruiting.
Non-inferiority margin for primary outcome not specified in registry entry.
Secondary outcomes, safety endpoints, and incidence of post-bariatric hypoglycemia outcomes not yet available.
Single-center design may limit generalizability.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Prospective, randomized, controlled non-inferiority design explicitly stated.

Directness

moderate

Primary outcome is hormonal response; clinical utility depends on postoperative hypoglycemia incidence.

Consistency

insufficient

No prior RCT comparing these procedures; consistency cannot be assessed.

Risk of bias

insufficient

Study is recruiting; blinding, allocation concealment, and outcome assessment details not reported.

Sample adequacy

limited

Estimated enrollment 32 participants; sample size justification not reported in registry.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07747779). This is a study registration, not published results. Lead sponsor: Chulalongkorn University. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 32 participants (ESTIMATED). Conditions: Bariatric Surgery, Hormonal Response, Post Bariatric Hypoglycemia. Interventions: PROCEDURE: Sleeve gastrectomy with duodenojejunal bypass; PROCEDURE: Roux-en-Y gastric bypass. Primary outcome measures: Hormonal response , Post-operative 6-24 months. Brief summary: Obesity is a major global health problem. Bariatric surgery is the most effective treatment, leading to substantial weight loss and improvement in obesity-related comorbidities. The most commonly performed procedures are Laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG). LRYGB is typically selected for patients with a BMI exceeding 50 kg/m2. Recently, LSG with duodenojejunal bypass (LSG-DJB) has been introduced. To date, no randomized controlled trial has compared LRYGB and LSG-DJB in patients with super morbid obesity, particularly regarding postoperative hormonal responses. This study aims to address this gap. If LSG-DJB results in a lower incidence of post-bariatric hypoglycemia than LRYGB, it would support its clinical benefit. Evaluation of GLP-1, GIP, glucagon, and insulin responses will clarify mechanisms underlying weight loss and postprandial glycemic changes.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Hormonal ResponsePost Bariatric HypoglycemiaSleeve gastrectomy with duodenojejunal bypassRoux-en-Y gastric bypassNCT07747779Chulalongkorn UniversityBariatric Surgery